异动解读｜科济药业-B盘中上涨5.51%，恺力美术后巩固治疗初步积极结果获ESMO年会壁报展示

行情直击07-16

7月16日，科济药业-B盘中上涨5.51%，报16.86港元，成交额2837.78万港元。

消息面上，公司于7月15日宣布，恺力美（舒瑞基奥仑赛注射液）在中国开展的针对胃/食管胃结合部腺癌术后辅助治疗后巩固治疗的研究者发起临床试验初步积极结果，已被欧洲肿瘤内科学会（ESMO）年会接受进行壁报展示。截至公告日，自临床试验启动入组以来，所有接受恺力美治疗的参与者均未发生胃癌术后复发或转移。恺力美为全球首个获批上市的实体瘤CAR-T细胞治疗产品，此次术后巩固治疗方向的探索进一步拓展了其适应症潜力，市场情绪延续利好。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1194794077?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-16 10:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194794077","market":"us","top_or_hot":-1,"title":"异动解读｜科济药业-B盘中上涨5.51%，恺力美术后巩固治疗初步积极结果获ESMO年会壁报展示","media":"行情直击","content":"<p><p>7月16日，科济药业-B盘中上涨5.51%，报16.86港元，成交额2837.78万港元。</p><p>消息面上，公司于7月15日宣布，恺力美（舒瑞基奥仑赛注射液）在中国开展的针对胃/食管胃结合部腺癌术后辅助治疗后巩固治疗的研究者发起临床试验初步积极结果，已被欧洲肿瘤内科学会（ESMO）年会接受进行壁报展示。截至公告日，自临床试验启动入组以来，所有接受恺力美治疗的参与者均未发生胃癌术后复发或转移。恺力美为全球首个获批上市的实体瘤CAR-T细胞治疗产品，此次术后巩固治疗方向的探索进一步拓展了其适应症潜力，市场情绪延续利好。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜科济药业-B盘中上涨5.51%，恺力美术后巩固治疗初步积极结果获ESMO年会壁报展示</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜科济药业-B盘中上涨5.51%，恺力美术后巩固治疗初步积极结果获ESMO年会壁报展示\n</h2>\n\n<h4 class=\"meta\">\n\n2026-07-16 10:27 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月16日，科济药业-B盘中上涨5.51%，报16.86港元，成交额2837.78万港元。消息面上，公司于7月15日宣布，恺力美（舒瑞基奥仑赛注射液）在中国开展的针对胃/食管胃结合部腺癌术后辅助治疗后巩固治疗的研究者发起临床试验初步积极结果，已被欧洲肿瘤内科学会（ESMO）年会接受进行壁报展示。截至公告日，自临床试验启动入组以来，所有接受恺力美治疗的参与者均未发生胃癌术后复发或转移。恺力美为全球...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1194794077","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194794077","pubTimestamp":1784168854,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"消息面上，公司于7月15日宣布，恺力美在中国开展的针对胃/食管胃结合部腺癌术后辅助治疗后巩固治疗的研究者发起临床试验初步积极结果，已被欧洲肿瘤内科学会年会接受进行壁报展示。截至公告日，自临床试验启动入组以来，所有接受恺力美治疗的参与者均未发生胃癌术后复发或转移。恺力美为全球首个获批上市的实体瘤CAR-T细胞治疗产品，此次术后巩固治疗方向的探索进一步拓展了其适应症潜力，市场情绪延续利好。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02171":"科济药业-B"},"translate_title":"Interpretation of abnormal changes | Keji Pharmaceutical-B rose by 5.51% in the intraday session, and the initial positive results of Kaili's post-art consolidation treatment were displayed in the ESMO annual meeting poster","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"7月16日，科济药业-B盘中上涨5.51%，报16.86港元，成交额2837.78万港元。消息面上，公司于7月15日宣布，恺力美（舒瑞基奥仑赛注射液）在中国开展的针对胃/食管胃结合部腺癌术后辅助治疗后巩固治疗的研究者发起临床试验初步积极结果，已被欧洲肿瘤内科学会（ESMO）年会接受进行壁报展示。截至公告日，自临床试验启动入组以来，所有接受恺力美治疗的参与者均未发生胃癌术后复发或转移。恺力美为全球首个获批上市的实体瘤CAR-T细胞治疗产品，此次术后巩固治疗方向的探索进一步拓展了其适应症潜力，市场情绪延续利好。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194794077","isCrawlerRequest":true}